Peripheal Artery Disease -Angioblast Systems, adult stem cells, repair, regeneration of blood vessels, adult stem cells technology, cardiovascular disease,

The use of MPCs to promote growth of new blood vessels will have direct application for patients with peripheral arterial disease (PAD) who number more than eight million in the US alone. Risk factors for PAD are similar to those for coronary artery disease.

They include high blood cholesterol, diabetes, smoking and obesity.

Most patients with significant PAD have diabetes, and the most common symptom is leg pain associated with exertion.

In severe cases, inadequate blood flow to the feet causes ulceration of wounds which fail to heal and can become gangrenous.

Thirty per cent of patients with existing PAD will ultimately require angioplasty to open the affected artery, and 10 per cent will require amputation of the affected limb within five to 10 years of diagnosis. Currently, there are more than 400,000 angioplasty procedures for PAD in the US . The number is expected to approach 640,000 by the end of 2005.

Angioblast plans to develop an MPC product for direct injection into the diseased artery at the time of angioplasty to increase the likelihood of long-term survival of the limb.



	**JavaScript based drop down DHTML menu generated by Visual QuickMenu Pro. (OpenCube Inc. - http://www.opencube.com)** Home Technology Overview FAQ Allogeneic Adult Stem Cells Protein Therapeutics Gene Silencing Applications Overview Heart Attack Congestive Heart Failure Peripheral Artery Disease Wound Ulcers Key Scientific Terms Adult Stem Cells Protein Therapeutics Gene Silencing Product Development Overview MPC Mesoblast Device Companies Clinical Network Management Board SAB News & Press Releases Publications Contact

	News
	9 April 2010 - ANGIOBLAST’S MARKET EXCLUSIVITY FOR ITS BIOLOGIC PRODUCTS STRENGTHENED BY NEW UNITED STATES HEALTH CARE ACT 18 December 2009 - SINGLE DOSE OF PROPRIETARY ADULT STEM CELLS REGENERATES DAMAGED PANCREAS AND REDUCES BLOOD GUCOSE LEVELS IN DIABETES 18 November 2009 - SUSTAINED SIX-MONTH IMPORVEMENT IN HEART MUSCLE FUNCTION BY “OFF-THE-SHELF” ADULT STEM CELLS 06 November 2009 - SUCCESSFUL BONE MARROW REGENERATION IN CANCER PATIENTS USING CORD BLOOD EXPANDED BY PROPRIETARY STEM CELLS 25 August 2009 - ANGIOBLAST CLOSES $10M EQUITY-BASED FINANCINGANGIOBLAST CLOSES $10M EQUITY-BASED FINANCING		The use of MPCs to promote growth of new blood vessels will have direct application for patients with peripheral arterial disease (PAD) who number more than eight million in the US alone. Risk factors for PAD are similar to those for coronary artery disease. They include high blood cholesterol, diabetes, smoking and obesity. Most patients with significant PAD have diabetes, and the most common symptom is leg pain associated with exertion. In severe cases, inadequate blood flow to the feet causes ulceration of wounds which fail to heal and can become gangrenous. Thirty per cent of patients with existing PAD will ultimately require angioplasty to open the affected artery, and 10 per cent will require amputation of the affected limb within five to 10 years of diagnosis. Currently, there are more than 400,000 angioplasty procedures for PAD in the US . The number is expected to approach 640,000 by the end of 2005. Angioblast plans to develop an MPC product for direct injection into the diseased artery at the time of angioplasty to increase the likelihood of long-term survival of the limb.